Lyell Immunopharma, Inc.
NASDAQ:LYEL
1.27 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.013 | 0.003 | 0.013 | 0.025 | 0.027 | 0.065 | 0.048 | 0.003 | 35.741 | 0.553 | 2.822 | 2.755 | 2.628 | 2.445 | 2.312 | 1.07 | 3.118 | 1.256 |
| Cost of Revenue
| 4.901 | 5.024 | 5.057 | 5.104 | 4.539 | 5.027 | 4.592 | 4.172 | 3.73 | 3.973 | 3.99 | 0 | 0 | 2.998 | 0 | 0 | 0 | 0 |
| Gross Profit
| -4.888 | -5.021 | -5.044 | -5.079 | -4.512 | -4.962 | -4.544 | -4.169 | 32.011 | -3.42 | -1.168 | 2.755 | 2.628 | -0.553 | 2.312 | 1.07 | 3.118 | 1.256 |
| Gross Profit Ratio
| -376 | -1,673.667 | -388 | -203.16 | -167.111 | -76.338 | -93.903 | -1,389.666 | 0.896 | -6.184 | -0.414 | 1 | 1 | -0.226 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 36.153 | 37.625 | 41.619 | 43.849 | 47.471 | 44.63 | 0.038 | 41.607 | 43.719 | 35.83 | 19.285 | 31.433 | 46.446 | 41.529 | 35.09 | 24.501 | 97.152 | 25.5 |
| General & Administrative Expenses
| 12.256 | 13.494 | 13.167 | 15.507 | 19.03 | 19.279 | 0.026 | 26.084 | 30.454 | 34.421 | 31.873 | 21.241 | 19.112 | 16.831 | 14.869 | 13.57 | 9.562 | 8.88 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.256 | 13.494 | 13.167 | 15.507 | 19.03 | 19.279 | 0.026 | 26.084 | 30.454 | 34.421 | 31.873 | 21.241 | 19.112 | 16.831 | 14.869 | 13.57 | 9.562 | 8.88 |
| Other Expenses
| -0.645 | 1.09 | -0.506 | 1.578 | -0.326 | -1.288 | 0.004 | -1.251 | -0.014 | -1.122 | -0.044 | 0.016 | -0.106 | -0.027 | 0.046 | 0.028 | 0.029 | 1.423 |
| Operating Expenses
| 48.409 | 51.119 | 54.786 | 59.064 | 65.932 | 62.621 | 0.068 | 66.44 | 73.002 | 69.129 | 50.36 | 51.916 | 65.335 | 57.815 | 41.836 | 37.913 | 105.684 | 34.26 |
| Operating Income
| -53.297 | -56.14 | -59.83 | -59.039 | -65.905 | -62.556 | -0.008 | -66.437 | -37.261 | -68.576 | -47.538 | -49.161 | -62.707 | -55.37 | -39.524 | -36.843 | -102.566 | -33.004 |
| Operating Income Ratio
| -4,099.769 | -18,713.333 | -4,602.308 | -2,361.56 | -2,440.926 | -962.4 | -0.174 | -22,145.667 | -1.043 | -124.007 | -16.845 | -17.844 | -23.861 | -22.646 | -17.095 | -34.433 | -32.895 | -26.277 |
| Total Other Income Expenses Net
| 7.488 | -4.527 | 6.9 | 1.578 | -3.249 | -4.403 | -175.917 | -3.817 | -0.014 | 0.432 | -36.491 | 0.016 | -0.106 | -0.027 | 0.046 | 0.028 | 0.029 | 1.423 |
| Income Before Tax
| -45.809 | -60.667 | -52.93 | -50.853 | -63.89 | -66.959 | -0.008 | -70.254 | -36.323 | -68.144 | -83.706 | -48.875 | -62.595 | -55.043 | -38.857 | -35.719 | -100.656 | -29.24 |
| Income Before Tax Ratio
| -3,523.769 | -20,222.333 | -4,071.538 | -2,034.12 | -2,366.296 | -1,030.138 | -0.174 | -23,418 | -1.016 | -123.226 | -29.662 | -17.74 | -23.818 | -22.512 | -16.807 | -33.382 | -32.282 | -23.28 |
| Income Tax Expense
| 0 | 4.981 | 5.013 | -6.608 | -2.341 | 65.671 | -2.447 | 3.817 | -0.952 | -0.432 | -0.323 | -0.27 | -0.218 | -0.354 | -1.288 | -1.096 | -1.881 | -2.341 |
| Net Income
| -45.809 | -60.667 | -52.93 | -50.853 | -63.89 | -132.63 | 2.439 | -74.071 | -36.323 | -67.712 | -83.706 | -48.875 | -62.595 | -55.043 | -38.857 | -35.719 | -100.656 | -29.24 |
| Net Income Ratio
| -3,523.769 | -20,222.333 | -4,071.538 | -2,034.12 | -2,366.296 | -2,040.462 | 50.399 | -24,690.333 | -1.016 | -122.445 | -29.662 | -17.74 | -23.818 | -22.512 | -16.807 | -33.382 | -32.282 | -23.28 |
| EPS
| -0.18 | -0.24 | -0.21 | -0.2 | -0.26 | -0.53 | 0.01 | -0.3 | -0.15 | -0.28 | -0.35 | -0.2 | -1.47 | -0.23 | -0.18 | -0.17 | -0.48 | -0.14 |
| EPS Diluted
| -0.18 | -0.24 | -0.21 | -0.2 | -0.26 | -0.53 | 0.01 | -0.3 | -0.15 | -0.28 | -0.35 | -0.2 | -1.47 | -0.23 | -0.18 | -0.17 | -0.48 | -0.14 |
| EBITDA
| -48.396 | -51.116 | -54.773 | -53.935 | -57.92 | -47.529 | -0.003 | -56.816 | -33.09 | -64.389 | -42.973 | -45.07 | -59.697 | -53.412 | -38.072 | -35.739 | -101.604 | -32.228 |
| EBITDA Ratio
| -3,722.769 | -17,038.667 | -4,213.308 | -2,157.4 | -2,145.185 | -731.215 | -0.069 | -18,938.667 | -0.926 | -116.436 | -15.228 | -16.359 | -22.716 | -21.845 | -16.467 | -33.401 | -32.586 | -25.659 |